| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Global Pharmaceutical Product Research Division, Abbott Laboratories, Abbott Park, Illinois and 2 Ligand Pharmaceuticals Inc., San Diego, California
Requests for reprints: Stephen K. Tahir, Cancer Research, Global Pharmaceutical Product Research Division, Dept. 4N6, AP9, 100, Abbott Laboratories, Abbott Park Road, Abbott Park, IL 60064-6099. Phone: 847-938-3709; Fax: 847-938-1674; E-mail: stephen.k.tahir{at}abbott.com.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
15% to 20% of all lung cancers, it is strongly associated with smoking and tends to grow and spread quickly. If left untreated, the median survival time of SCLC patients is 2 to 4 months (2). Initially, most SCLC tumors respond to chemotherapy and radiotherapy. Typical chemotherapies involve platinum-based regimens combined with etoposide (3–5). Unfortunately, relapse is common because the tumors become resistant to further treatment, with a 5-year survival rate of 5% to 10%. One of the factors implicated in the resistance of SCLC to chemotherapy is the overexpression of the antiapoptotic protein Bcl-2 (6–9). Unlike other oncogenes, Bcl-2 promotes tumorigenesis by attenuating cell death as opposed to promoting cell proliferation (10, 11). Thus, Bcl-2 allows tumor cells to ignore environmental cues that signal cells to undergo apoptosis. The bcl-2 oncogene was the first member of about 20 evolutionary conserved genes identified that encode closely related proteins that possess either proapoptotic or antiapoptotic activity (11, 12). The interaction of the Bcl-2 family members with each other is largely responsible for the commitment of cells to undergo apoptosis (13). One distinguishing feature is that they share up to four Bcl-2 homology (BH) domains (14). The multidomain antiapoptotic Bcl-2 members, such as Bcl-XL, Bcl-2, Bcl-w, A1, and Mcl-1, inhibit cytochrome c release by blocking the activation of the multidomain proapoptotic proteins Bax and Bak (15). Bax and Bak are direct mediators of apoptosis and are absolutely required for the initiation of the mitochondrial apoptosis pathway (16, 17). The other proapoptotic members, such as Bad, Bik, Bid, Bim, Hrk, Bmf, Noxa, and Puma, act as molecular sensors of cellular stress or damage (18). They are distinguished from Bax and Bak in that they possess only the BH3 domain. They are mobilized and activated to initiate apoptosis by modulating the activity of the other Bcl-2 family members (17, 19–22).
The overexpression of Bcl-2 has been observed in a variety of cancers and contributes to chemotherapeutic resistance (23). In SCLC patients, the overexpression of Bcl-2 has been reported to occur in 55% to 90% of all SCLC cases, and it has been suggested to be a key factor involved in both the genesis and maintenance of SCLC (24–28). Studies have shown that Bcl-2 also plays a direct role in SCLC cell resistance to external apoptotic stimuli (8, 9, 29, 30). For example, the apoptotic response of SCLC cells to mitomycin C, irinotecan, and Adriamycin could be inhibited by ectopically overexpressing Bcl-2 (8). Conversely, treatment with Bcl-2 antisense oligodeoxynucleotides acted synergistically with etoposide, doxorubicin, and cisplatin to enhance the cell killing of SCLC cell lines in vitro (31).
There have been several efforts to target Bcl-2 family members for the treatment of neoplastic disease given their association with cancer and resistance to numerous cytotoxic drugs (32–34). Recently, we reported the discovery and biological properties of ABT-737, a novel and potent Bcl-2 antagonist developed at Abbott Laboratories (35). ABT-737 binds with high affinity (Ki 
1 nmol/L) to Bcl-2, Bcl-XL, and Bcl-w and is two to three orders of magnitude more potent than previously reported compounds (36). ABT-737 does not, however, bind strongly to Bcl-B, Mcl-1, or A1 (Ki = 0.46 ± 0.11, >1, and >1 µmol/L, respectively). ABT-737 exhibited single-agent activity against several cell lines in vitro and in vivo. However, the response varied depending on the cell line, indicating that one or more cellular-based mechanisms were contributing to the sensitivity to ABT-737.
Here, we evaluated the contribution of Bcl-2 and other Bcl-2 family members to the cellular response of SCLC cell lines to ABT-737 by first establishing the co-relationship of Bcl-2 family members with sensitivity to ABT-737 in a panel of 11 naïve SCLC cell lines and in the progressive adaptation of the sensitive cell line H146 to ABT-737. Because correlative expression may only be an epiphenomenon, we evaluated the mechanistic contribution of two family members, Mcl-1 and Noxa, to SCLC cellular resistance to ABT-737 by down-regulating Mcl-1 or ectopically overexpressing Noxa in resistant SCLC cell lines. Finally, we show that the cellular sensitivity of H196 cells treated in combination with DNA-damaging agents and ABT-737 was synergistic, and that the increase in sensitivity was associated with decreased Mcl-1 levels and increased levels of the BH3-only proteins Noxa, Puma, and Bim.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell culture. The SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI 1640 (Invitrogen Corp., Grand Island, NY) supplemented with 10% fetal bovine serum (Invitrogen), 1% sodium pyruvate, 25 mmol/L HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin (Sigma). All cell lines were maintained in a humidified chamber at 37°C containing 5% CO2.
The ABT-737–resistant H146 cells were derived from H146 cells by initially adding 40 nmol/L ABT-737 to their culture medium and thereafter doubling the concentration over a period of several months. Several drug-resistant variants that adapted to and maintained in the presence of 40, 80, 160, 320, 640 and 1,280 nmol/L ABT-737 were generated in this manner and were designated as H146-40, H146-80, etc.
Cell treatment and viability assays. Cells were treated for 48 h in 96-well tissue culture plates in a total volume of 100 µL tissue culture medium supplemented with 10% human serum (Invitrogen). Each concentration was tested in duplicate at least thrice separately. Viable cells were determined using the CellTiter 96 AQueous nonradioactive cell proliferation MTS assay (Promega Corp., Madison, WI). The activation of caspase 3 was measured by the cleavage of the fluorometric substrate Ac-DEVD-AMC (Biomol Research Laboratories, Plymouth Meeting, PA) or Z-DEVD-R110 (Promega) as described previously (37). For combination treatment, H196 cells were plated at 1 x 104 cells/100 µL and treated concurrently with increasing concentrations of carboplatin/etoposide (at a fixed ratio of 2.5:1) and ABT-737 in the presence of 10% human serum for 72 h. Cell viability was determined using Promega's CellTiter Glo assay. The combination index (CI) as described by Chou and Talalay (38) was assessed using the software program CalcuSyn (Biosoft, Ferguson, MO) to quantitatively assess the effect of drug-combination treatment. A CI value of 1.0 indicated an additive effect, CI values of <1.0 reflected a synergistic effect, and a CI value of >1.0 reflected an antagonistic effect.
Western blot analysis. Total protein from cell lysates were separated on 4% to 20% gels by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Invitrogen, Carlsbad, CA). The membranes were blocked with TBS containing 5% nonfat dry milk and 0.1% Tween 20 (blocking buffer) for 1 h at room temperature and then incubated overnight at 4°C with antibodies diluted in blocking buffer. We used anti–Bcl-XL (1 µg/mL; 2300-MC), anti-Bax (1 µg/mL; 840714), and anti-Bid (1 µg/mL; AF-846) from R&D Systems (Minneapolis, MN); anti–Bcl-2 (1:500; 610539) and anti–Mcl-1 (1:500; 554103) from BD PharMingen (San Diego, CA); anti-Bak (1:1,000; 3792) and anti-
Puma (1:250; 4976) from Cell Signaling (Beverly, MA); anti-Bim (1 µg/mL; AAP-330) from Stressgen (Victoria, BC); anti-Noxa (2 µg/mL; IMG-349) from Imgenex (San Diego, CA); and anti-actin (1:10,000; ab6276) from Abcam (Cambridge, MA). Primary antibodies were detected using either a goat anti-mouse or goat anti-rabbit horseradish peroxidase–conjugated secondary antibody (Pierce Biotechnology, Rockford, IL) diluted 1:500 in blocking buffer for 0.5 h at room temperature. The membranes were washed after each antibody step thrice for 5 min with TBS containing 0.2% Tween 20. Bands were detected using Enhanced Chemiluminescence Plus (GE Healthcare, Piscataway, NJ) and a STORM 860 molecular imager (GE Healthcare). Quantitation of the protein level changes was done by densitometry using ImageQuant (GE Healthcare). The percent increase in protein levels is defined as ((band intensity at time x – band intensity at time 0 h)/band intensity at time 0 h) x 100%.
Transfection protocols. H196 cells were plated at 1 x 104 cells/100 µL in 96-well tissue culture plates and allowed to attach overnight. Small interfering (si) RNA transfections were done using four siRNA duplexes directed at different regions of the Mcl-1 gene (M-004501-02, M-004501-07, M-004501-08, and M-004501-09, designated as siRNA-1, siRNA-2, siRNA-3, and siRNA-4, respectively) or scrambled siRNA pool (four negative control siRNAs, D-001206-13) from Dharmacon (Lafayette, CO). For Mcl-1 siRNA transfections, 1.5 µL of a 20-µmol/L stock of Mcl-1 siRNAs and 3 µL of LipofectAMINE 2000 (Invitrogen) were each incubated separately with 100 µL Opti-MEM (Invitrogen) for 10 min, mixed together for 20 min at room temperature, and then 20 µL was applied to the cells (final siRNA concentration was 25 nmol/L). After incubating the cells for 3 to 4 h, the medium was changed to RPMI supplemented with 10% human serum. The following day, siRNA-transfected cells were either treated with ABT-737 for 48 h, and cell viability was assessed using Perkin-Elmer's (Boston, MA) ATPlite assay and used to measure the cleavage of Z-DEVD-R110 before and 6 h after the addition of ABT-737 to assess the induction of apoptosis. DMS114 siRNA transfections were done using the siRNA duplex for Mcl-1 (M-004501-02; siRNA-1), or scrambled siRNA (D-001210-01) from Dharmacon as described above, and their viability was determined using the MTS assay.
For Noxa transfections, H196 were plated at 6.0 to 7.5 x 105 cells in six-well tissue culture plates and allowed to attach overnight. The Flag-tagged Noxa expression vector (1 or 2 µg, GN012925, RefSeq no. NM_021127, Genscript Corp., Piscataway, NJ) or control pDream2.1-cGFP vector (SD0220, Genscript) were diluted in 250 µL Opti-MEM (Invitrogen), and 10 µL LipofectAMINE 2000 (Invitrogen) was added to 250 µL Opti-MEM. Both were incubated for 10 min separately and then together for 20 min at room temperature. The mixture (500 µL) was added to the cells in 2 mL of culture medium. After incubating the cells for 3 h, the medium was changed with fresh medium containing 10% human serum. The following day, plasmid-transfected cells were transferred to 96-well plates at 10 x 104 cells per well and treated with ABT-737 for 48 h in medium containing 10% human serum. Cell viability was assessed using Promega's MTS assay.
Microarray analysis. Total RNA was isolated from cell lines, and 5 µg was used for microarray analysis using the standard protocol provided by Affymetrix Inc. (Santa Clara, CA). Fragmented, labeled cRNA synthesized using an IVT labeling kit, (Enzo, New York, NY) was hybridized to an Affymetrix human genome U133A version 2.0 Affymetrix microarrays at 45°C overnight. The scanned image and intensity files were imported in the Rosetta Resolver gene expression analysis software version 5.1 (Rosetta Inpharmatics, Kirkland, WA). Resolver's Affymetrix error model was applied, and replicates were combined. Combined intensity values were exported into Spotifire (Spotifire, Inc., Somerville, MA) to generate heat maps, with red indicating a high expression and green indicating a low expression using intensity z score values normalized for each gene individually, across all experiments being analyzed. Expression profiles were derived from mRNA from two or more independent samples for each cell line.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
Bcl-2 and Noxa levels decrease and Mcl-1 levels increase in H146 cells following chronic exposure to ABT-737. We next evaluated the relative changes to the expression levels of Bcl-2 family members in H146 cells that became progressively resistant to ABT-737 following continuous exposure for several months. Several drug-resistant variants that were adapted to and maintained in the presence of 40, 80, 160, 320, 640, and 1,280 nmol/L ABT-737 were generated. The cellular sensitivity for the resistant variants ranged from an EC50 of 100 nmol/L for the parental cells up to 1.5 µmol/L for the H146-1280–resistant variants (Fig. 3A ).
|
Decrease in Mcl-1 expression with siRNA sensitizes H196 cells to ABT-737. Given that expression correlations alone are not sufficient to show a mechanistic role in resistance, functional validation studies were conducted using RNAi technology. We initially transfected one of the highly resistant SCLC cell lines, H196, with Mcl-1 siRNA to show a causal relationship between Mcl-1 expression and cellular resistance to ABT-737. H196 cells (EC50 55 µmol/L) were transfected with four different Mcl-1–specific siRNAs at a final concentration of 25 nmol/L and then treated with or without 20 µmol/L ABT-737 (EC20). Transfection with each of the four Mcl-1 siRNAs resulted in knockdown in Mcl-1 protein levels compared with the scrambled siRNA control, but had minimal effects on cell growth alone (Fig. 4A and B
). Importantly, Mcl-1 knockdown in the presence of ABT-737 corresponded to enhanced H196 cell death (Fig. 4B). Notably, siRNA-1 and siRNA-4 that decreased Mcl-1 levels to the greatest extent also sensitized H196 cells to ABT-737 to the greatest degree. There was a clear dose response to ABT-737 in the presence of 25 nmol/L Mcl-1 siRNA-1 with an apparent EC50 of 0.14 µmol/L, which represented approximately a 400-fold increase in the sensitivity of H196 cells to ABT-737 treatment (Fig. 4C). Increased sensitivity to ABT-737 was also observed following Mcl-1, but not scrambled siRNA transfection of the most resistant SCLC cell line, DMS114 (Fig. 4C). Unlike H196, however, the viability of DMS114 cells was reduced by >50% following Mcl-1 siRNA transfection alone and was further reduced following treatment with ABT-737. The apparent EC50 of ABT-737 in DMS114 cells following Mcl-1 transfection was <0.2 µmol/L. In both cells lines, an analogous dose response in the presence of 25 nmol/L scrambled siRNA did not enhance the cellular sensitivity of ABT-737, suggesting that the increased sensitivity was specific to the knockdown of Mcl-1 and not due to the transfection conditions alone.
|
Noxa overexpression sensitizes H196 cells to ABT-737. To investigate the relationship between Noxa and cellular response to ABT-737, we transfected H196 cells with a Noxa or control expression vector, and cell viability was accessed following treatment with or without 20 µmol/L ABT-737. Transfection with the Noxa expression vector resulted in enhanced expression of Noxa (Fig. 5A
). The increased expression of either Noxa or ABT-737 treatment alone slightly reduced the viability of H196 cells. However, the combination of both Noxa overexpression and ABT-737 treatment decreased H196 viability by 50% to 60% as compared with the nontransfected controls (Fig. 5B). The viability of the control vector–transfected cells was similar to the nontransfected controls, suggesting that the increased sensitivity to ABT-737 was due to the expression of Noxa and not the transfection conditions alone.
|
90% of untreated controls following treatment with 1.56 µmol/L ABT-737 and 70%, 60%, and 40% following treatment with 4.7:1.9, 9.4:3.8, or 75:30 µmol/L carboplatin/etoposide, respectively, for 72 h (Fig. 6A
). In contrast, cell viability following concurrent treatment with 4.7:1.9, 9.4:3.8, or 75:30 µmol/L carboplatin/etoposide with 1.56 µmol/L ABT-737 was 40%, 30%, and 20%, respectively. The CI as described by Chou and Talalay (38) was used to quantitatively assess the effect of the drug-combination treatment where the ratio of carboplatin, etoposide, and ABT-737 was kept at a fixed ratio of 48:19:1, respectively. The CI values between the dose-effect levels 0.50 to 0.90 were <0.3, indicating that the combination of carboplatin/etoposide and ABT-737 was strongly synergistic (Fig. 6B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To evaluate the mechanistic contribution of Bcl-2 family members to the cellular response to ABT-737, we used both molecular and chemical approaches. We found that Mcl-1 knockdown sensitized SCLC cells to ABT-737 treatment by enhancing ABT-737–induced apoptosis. Mcl-1 knockdown seems to contribute to ABT-737 sensitivity by lowering the apoptotic threshold which is consistent with previous reports that show Mcl-1 and Bcl-XL both are potent inhibitors of apoptosis by inhibiting Bak activation (13, 20). The enhanced apoptosis when ABT-737 was used in combination with Mcl-1 knockdown indicates further that Mcl-1 is an important regulator of apoptosis, and that the combination of ABT-737 with other treatment therapies that modulate Mcl-1 has potential utility in SCLC malignancies.
Of interest, we observed that there was an increase in apoptosis in DMS114 cells following Mcl-1 knockdown alone. This is consistent with the idea that some cells are "primed for death," and that they are dependent or "addicted" to certain Bcl-2 family members for survival (40). In this case, Mcl-1 would seem to play a crucial role in DMS114 cell survival, and inhibition of other antiapoptotic proteins such as Bcl-XL can further enhance cell death. Thus, Mcl-1 may play a critical role in SCLC drug resistance to ABT-737 by functionally compensating for other Bcl-2 antiapoptotic family members.
Here, we show that up-regulation of the BH3-only protein Noxa increased the sensitivity of H196 cells to ABT-737. The BH3-only proteins act as molecular sensors of cellular stress or damage, and they are activated to initiate apoptosis by modulating the activity of the other Bcl-2 family members (17–22). Recently, Noxa has been shown to specifically bind to Mcl-1 and A-1 but not Bcl-2, Bcl-XL, or Bcl-w (19). This highly specific interaction of Noxa for Mcl-1 suggests that it is a key regulator of Mcl-1. This was shown previously in transformed mouse embryo fibroblast cells where overexpression of Noxa was shown to promote Mcl-1 but not Bcl-XL degradation and promote the release of proapoptotic Bak from Mcl-1 (20). Furthermore, it was shown that Bak binds to both Bcl-XL and Mcl-1, and that a loss of Bcl-XL sensitized mouse embryo fibroblasts to Noxa-induced killing (20). Coincidentally, we observed higher Noxa levels in cell lines sensitive to ABT-737, and ectopic expression of Noxa in a resistant cell line increased their sensitivity to ABT-737. This suggests that Noxa may play an important role in governing the cellular response of SCLC cells to ABT-737, in part by neutralizing Mcl-1 in SCLC cells.
Carboplatin, cisplatin, and etoposide are cytotoxic agents that interfere with the DNA replication process during S phase and elicit a DNA damage response that causes cells to arrest and undergo apoptosis (41, 42). In cells containing wild-type p53, p53 induces the transcriptional up-regulation of several proapoptotic genes including BAX, PUMA, and NOXA (39). Here, we show that combination treatment with carboplatin/etoposide and ABT-737 was extremely synergistic (CI < 0.3). This was associated with the down-regulation of Mcl-1 and the concerted up-regulation of multiple BH3-only proteins Noxa, Puma, and Bim. Noxa, Puma, and Bim have been shown to be potent inducers of apoptosis (13, 17, 19). Unlike Noxa, however, Puma and Bim bind with high affinity to all of the multidomain antiapoptotic Bcl-2 family members (19). Thus, ABT-737 synergism with carboplatin/etoposide may involve in part the combined activities of BH3-only proteins to neutralize the prosurvival activity of Mcl-1, together with the inhibition of Bcl-2/Bcl-XL by ABT-737. This suggests that the chemotherapeutics that neutralize Mcl-1 either directly or indirectly by modulating key factors that regulate it will enhance the activity of ABT-737.
Thus, a balance between antiapoptotic and proapoptotic proteins seems to govern the cellular response of SCLC cells to ABT-737. Presumably, the presence of intrinsic and extrinsic death signals necessitates the expression of one or more antiapoptotic Bcl-2 family members for SCLC survival. In SCLC cell lines sensitive to ABT-737, the expression of Bcl-2, Bcl-XL, and, to a lesser extent, Mcl-1 governs cell survival. In SCLC cell lines resistant to ABT-737, elevated Mcl-1 expression seems to compensate for the decreased expression of Bcl-2 and Bcl-XL. Lower expression levels of Noxa in resistant cell lines would further increase the antiapoptotic potency of Mcl-1. Similarly, lower levels of Puma and Bim would also increase the antiapoptotic potency of all prosurvival members. Overall, these data suggest that cell dependence on Bcl-2 and Bcl-XL for survival is requisite for cellular sensitivity to ABT-737, and their absence is indicative of resistance in SCLC cell lines. Conversely, the presence of Mcl-1 alone does not necessarily signify resistance; however, higher Mcl-1 expression may be one mechanism by which resistance can occur.
In summary, these findings provide compelling evidence that certain Bcl-2 family members play a role in the cellular response of SCLC cell lines to ABT-737. In a broader context, our results provide information that may be useful in the development of biomarkers for the stratification of SCLC patients and the design of better rational-based combination therapies for clinical trials. In addition, they provide further insight into the relative contribution and interaction of Bcl-2 family members in regulating apoptosis in SCLC that may lead to the design of more effective targeted therapies in the future.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Received 6/15/06. Revised 11/ 3/06. Accepted 11/20/06.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. Chen, Y. Dai, X.-Y. Pei, and S. Grant Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1 Mol. Cell. Biol., December 1, 2009; 29(23): 6149 - 6169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Kim, L. Moretti, L. R. Mitchell, D. K. Jung, and B. Lu Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model Clin. Cancer Res., October 1, 2009; 15(19): 6096 - 6105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bray, H.-Y. Chen, C. M. Karp, M. May, S. Ganesan, V. Karantza-Wadsworth, R. S. DiPaola, and E. White Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer Mol. Cancer Res., September 1, 2009; 7(9): 1487 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Yang, D. Barbone, D. A. Fennell, and V. C. Broaddus Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 14 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Li, Y. Zang, C. Li, N. S. Patel, J. R. Grandis, and D. E. Johnson ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated Pathway Mol. Pharmacol., May 1, 2009; 75(5): 1231 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vogler, M. Butterworth, A. Majid, R. J. Walewska, X.-M. Sun, M. J. S. Dyer, and G. M. Cohen Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia Blood, April 30, 2009; 113(18): 4403 - 4413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hauck, B. H. Chao, J. Litz, and G. W. Krystal Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737 Mol. Cancer Ther., April 1, 2009; 8(4): 883 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Whitecross, A. E. Alsop, L. A. Cluse, A. Wiegmans, K.-M. Banks, C. Coomans, M. J. Peart, A. Newbold, R. K. Lindemann, and R. W. Johnstone Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors Blood, February 26, 2009; 113(9): 1982 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kang and C. P. Reynolds Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy Clin. Cancer Res., February 15, 2009; 15(4): 1126 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Huang, K. Okumura, and F. A. Sinicrope BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., January 1, 2009; 15(1): 150 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okumura, S. Huang, and F. A. Sinicrope Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737 Clin. Cancer Res., December 15, 2008; 14(24): 8132 - 8142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Mason, C. J. Vandenberg, C. L. Scott, A. H. Wei, S. Cory, D. C. S. Huang, and A. W. Roberts In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas PNAS, November 18, 2008; 105(46): 17961 - 17966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Micha, J. Cummings, A. Shoemaker, S. Elmore, K. Foster, M. Greaves, T. Ward, S. Rosenberg, C. Dive, and K. Simpson Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7304 - 7310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Song, K. Kandasamy, and A. S. Kraft ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis J. Biol. Chem., September 5, 2008; 283(36): 25003 - 25013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Shoemaker, M. J. Mitten, J. Adickes, S. Ackler, M. Refici, D. Ferguson, A. Oleksijew, J. M. O'Connor, B. Wang, D. J. Frost, et al. Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., June 1, 2008; 14(11): 3268 - 3277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Konopleva, J. Watt, R. Contractor, T. Tsao, D. Harris, Z. Estrov, W. Bornmann, H. Kantarjian, J. Viallet, I. Samudio, et al. Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax) Cancer Res., May 1, 2008; 68(9): 3413 - 3420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tse, A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen, S. Jin, E. F. Johnson, K. C. Marsh, M. J. Mitten, P. Nimmer, et al. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Cancer Res., May 1, 2008; 68(9): 3421 - 3428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kang, Z. Wan, Y. H. Kang, R. Sposto, and C. P. Reynolds Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation J Natl Cancer Inst, April 16, 2008; 100(8): 580 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Hann, V. C. Daniel, E. A. Sugar, I. Dobromilskaya, S. C. Murphy, L. Cope, X. Lin, J. S. Hierman, D. L. Wilburn, D. N. Watkins, et al. Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer Cancer Res., April 1, 2008; 68(7): 2321 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Del Gaizo Moore, K. D. Schlis, S. E. Sallan, S. A. Armstrong, and A. Letai BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia Blood, February 15, 2008; 111(4): 2300 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. De Biasio, J. A. Vrana, P. Zhou, L. Qian, C. K. Bieszczad, K. E. Braley, A. M. Domina, S. J. Weintraub, J. M. Neveu, W. S. Lane, et al. N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells J. Biol. Chem., August 17, 2007; 282(33): 23919 - 23936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai and S. Grant Targeting Multiple Arms of the Apoptotic Regulatory Machinery Cancer Res., April 1, 2007; 67(7): 2908 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Olejniczak, C. Van Sant, M. G. Anderson, G. Wang, S. K. Tahir, G. Sauter, R. Lesniewski, and D. Semizarov Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains Mol. Cancer Res., April 1, 2007; 5(4): 331 - 339. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
